Actively Recruiting
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
Led by Yonsei University · Updated on 2025-05-21
3520
Participants Needed
1
Research Sites
392 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.
CONDITIONS
Official Title
DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 years or older
- Candidates for treatment with a drug-coated or drug-eluting stent due to acute coronary syndrome
- Provided informed consent to participate
You will not qualify if you...
- Current or potential pregnancy
- Need for oral anticoagulation therapy
- Unable to be followed for 1 year after enrollment as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea
Actively Recruiting
Research Team
C
Chul-Min Ahn
CONTACT
S
Sung-Jin Hong, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here